What we do

We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses, scientific and technical know-how and talented people.

Our three global businesses

cancer cell_T cell


Our Pharmaceutical business has a broad portfolio of innovative and established medicines. We currently focus on developing new medicines in respiratory and HIV/infectious diseases, oncology and immuno-inflammation; with discovery research exploring these and other areas.

Image: Illustration of t-cells engaging and destroying the cancer cellImmune system T-cells attacking a cancer cell

meningococcal bacteria


Our Vaccines business has a broad portfolio and innovative pipeline of vaccines to protect people of all ages. We deliver over two million vaccine doses per day to people living in over 160 countries.

Image: Meningococcal serogroup B bacteria, commonly known as meningitis B


Consumer Healthcare

Our Consumer Healthcare business develops and markets consumer preferred and expert recommended brands in the oral health, pain relief, respiratory, nutrition/gastro-intestinal and skin health categories.

Image: Novamin, which helps to repair and protect sensitive teeth

On December 19, 2018 we announced our agreement with Pfizer to form a new world-leading Consumer Healthcare Joint Venture. Within 3 years of the closing of the transaction, we intend to separate the Joint Venture via a demerger. With our future intention to separate, the transaction also presents a clear pathway forward for us to create a new global Pharmaceuticals/Vaccines company, and a new world-leading Consumer Healthcare company. Find out more